Full Name
Dr. Iskra Pusic MD, MSCI
Job Title
Professor, Department of Medicine, Division of Oncology
Company/Affiliation
Washington University
Speaker Bio
Dr. Pusic is a Professor in the Division of Oncology at Washington University School of Medicine in St. Louis, MO. She specializes in the treatment of adults with hematological malignancies, with a focus on hematopoietic cell transplantation (HCT) and cellular therapies. Her clinical research centers on the long-term complications following HCT and cellular therapies, particularly the prevention and treatment of Graft-versus-Host Disease (GvHD) and survivorship.
She participated in the 2014 and 2021 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD, the most comprehensive, detailed, and universally accepted guidelines for chronic GVHD diagnosis and management. She has conducted several investigator-initiated trials and served as co-PI for numerous large multicenter transplant and GVHD studies (both through large national consortia and industry-sponsored).
Dr. Pusic is the Institutional PI for Washington University as a Core Clinical Center at the Blood & Marrow Transplant Clinical Trials Network (BMT CTN). At BMT CTN, she served as co-investigator on many multicenter studies, was on the protocol development team for protocol #2002 (T-Guard), participated in the 2021 State of Science Symposia, and is a member of the Toxicity and Supportive Care Committee. Currently, she is a co-chair for the BMT CTN protocol #2023 development team, focused on mesenchymal stromal cells for treatment of refractory acute GVHD.
In 2022, she received the American Society of Transplantation and Cellular Therapy (ASTCT) Leadership Course Award. At ASTCT, she is a member of the Survivorship SIG Steering Committee, the Committee on Practice Guidelines, the Women and URM SIG, and the ACCESS Initiative. In addition, she serves on the National Comprehensive Cancer Network Chronic Myeloid Leukemia panel. She also has extensive experience in critical review and appraisal of clinical studies through her service on several review committees, including the monthly Protocol Review Monitoring Committee and bi-monthly Data Safety Monitoring Board (DSMB) within her institution, as well as the DSMB at the Center for International Blood and Marrow Transplant Research (CIBMTR).
She participated in the 2014 and 2021 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD, the most comprehensive, detailed, and universally accepted guidelines for chronic GVHD diagnosis and management. She has conducted several investigator-initiated trials and served as co-PI for numerous large multicenter transplant and GVHD studies (both through large national consortia and industry-sponsored).
Dr. Pusic is the Institutional PI for Washington University as a Core Clinical Center at the Blood & Marrow Transplant Clinical Trials Network (BMT CTN). At BMT CTN, she served as co-investigator on many multicenter studies, was on the protocol development team for protocol #2002 (T-Guard), participated in the 2021 State of Science Symposia, and is a member of the Toxicity and Supportive Care Committee. Currently, she is a co-chair for the BMT CTN protocol #2023 development team, focused on mesenchymal stromal cells for treatment of refractory acute GVHD.
In 2022, she received the American Society of Transplantation and Cellular Therapy (ASTCT) Leadership Course Award. At ASTCT, she is a member of the Survivorship SIG Steering Committee, the Committee on Practice Guidelines, the Women and URM SIG, and the ACCESS Initiative. In addition, she serves on the National Comprehensive Cancer Network Chronic Myeloid Leukemia panel. She also has extensive experience in critical review and appraisal of clinical studies through her service on several review committees, including the monthly Protocol Review Monitoring Committee and bi-monthly Data Safety Monitoring Board (DSMB) within her institution, as well as the DSMB at the Center for International Blood and Marrow Transplant Research (CIBMTR).
Speaking At
